http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20070045346-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4706
filingDate 2005-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff02e103d0a126698b0952036407e126
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae204f5170a2118062a0aa850f29a886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea7a0e34f912d702a831a5a00a4e6ddb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9393652a30d3fd83bd4a138e85a6993
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78402997d7e4db8c98df4af9f424fbef
publicationDate 2007-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-20070045346-A
titleOfInvention 4-Amino-substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
abstract The present invention provides a 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compound of formula (I); Pharmaceutical compositions containing this compound; And low levels of HDL cholesterol and / or high concentrations of LDL-cholesterol and / or high concentrations of certain plasma lipids, including high density lipoprotein (HDL) -cholesterol and lowering certain other plasma lipid concentrations, such as low density lipoprotein (LDL) -cholesterol and triglycerides. It relates to the use of such compounds for the treatment of atherosclerosis and cardiovascular diseases in some mammals, including diseases affected by triglycerides, for example humans.n n n Formula I
priorityDate 2004-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467898651
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465119864
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID58615277

Total number of triples: 30.